Access Industries and Takeda scored exits as the oncology therapy developer floated at the top of its range in an upsized offering.
Day One Biopharmaceuticals, a US-based cancer drug developer backed by conglomerate Access Industries and pharmaceutical firm Takeda, floated yesterday in a $160m upsized initial public offering.
The company issued 10 million shares on the Nasdaq Global Select Market priced at $16 per share, at the upper end of the IPO’s $14 to $16 range. Its shares closed at $25.89 on the first day of trading, representing a market capitalisation of approximately $1.56bn.
Founded in 2018, Day One is developing drug…
